Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection

NCT03074331 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03074331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03074331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 23, 2017
Completion date
February 7, 2018
Enrollment
130 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection